AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3281412 — intervention group
Group type: COMPARATOR
Intervention: Placebo (early treatment, ≤ 8 hours after onset of pain)
Number of subjects: 1395
Study 3281412 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (late treatment, > 8 hours after onset of pain)
Number of subjects: 1395
Study 3281412 — intervention group
Group type: COMPARATOR
Intervention: Placebo (late treatment, > 8 hours after onset of pain)
Number of subjects: 1395
Study 8181329 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough (30 coughs over a 10-min period)
Number of subjects: 14
Study 8181329 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced expiration (30 forced expirations over a 10-min period)
Number of subjects: 14
Study 8181329 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study 14740680 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 26
Study 14740680 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 26
Study 30326790 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic warm-up
Number of subjects: 23
Study 30326790 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance-band warm-up
Number of subjects: 23
Study 30326790 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 23
Study 28437520 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate
Number of subjects: 920
Study 28437520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 920
Study 25928009 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated maternal health intervention (training and deployment of Community Based Skilled Birth Attendants)
Number of subjects: 3000
Study 23706048 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained low-efficiency dialysis (SLED)
Number of subjects: 10
Study 23706048 — intervention group
Group type: COMPARATOR
Intervention: Continuous veno-venous hemofiltration (CVVH)
Number of subjects: 10
Study 20102772 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise (70% of peak oxygen uptake)
Number of subjects: 9
Study 20102772 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity aerobic exercise (50% of peak oxygen uptake)
Number of subjects: 9
Study 20209976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger-partitioned moxibustion
Number of subjects: 209
Study 20209976 — intervention group
Group type: COMPARATOR
Intervention: Medication (Yueyueshu Granules)
Number of subjects: 209
Study 17549294 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (5-60 mg, oral, twice-daily)
Number of subjects: 1343
Study 17549294 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (40 mg once daily before THR, 30 mg bid after TKR)
Number of subjects: 1343
Study 17549294 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 1343
Study 17549294 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (5-20 mg)
Number of subjects: 1343
Study 15302725 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity inspiratory muscle training (IMT) at 80% of maximal effort (group 1)
Number of subjects: 29
Study 15302725 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity inspiratory muscle training (IMT) at 20% of maximal effort (group 2)
Number of subjects: 29
Study 15302725 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 3)
Number of subjects: 29
Study 11477494 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (8 week supervised program, aerobic exercise at 75% VO(2) peak, 45 min, twice a week; intermittent exercise once a week)
Number of subjects: 16
Study 11477494 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 16
Study 9495222 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (1000 mg every 8 hours) with zidovudine (AZT)
Number of subjects: 26
Study 9495222 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (1000 mg every 8 hours) with didanosine (ddI) administered sequentially (2 hours before ganciclovir)
Number of subjects: 26
Study 9495222 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (1000 mg every 8 hours) with didanosine (ddI) administered simultaneously
Number of subjects: 26
Study 9495222 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (1000 mg every 8 hours) with probenecid
Number of subjects: 26
Study 9495222 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (1000 mg every 8 hours) administered 2 hours after didanosine (ddI)
Number of subjects: 26
Study 9495222 — intervention group
Group type: COMPARATOR
Intervention: Oral ganciclovir (1000 mg every 8 hours) with no coadministration
Number of subjects: 26
Study 8053737 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 15
Study 8053737 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 15
Study 2902319 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 mg/m2 by mouth, nightly for 6 months)
Number of subjects: 12
Study 2902319 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 6 months)
Number of subjects: 12
Study 29939961 — intervention group
Group type: EXPERIMENTAL
Intervention: Interoceptive Exposure (IE) therapy
Number of subjects: 126
Study 29939961 — intervention group
Group type: COMPARATOR
Intervention: Relaxation Therapy (RT)
Number of subjects: 126
Study 28614188 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham opioid solution (NaCl) with verbal instruction that it reduces pain and improves physical capacity
Number of subjects: 48
Study 28614188 — intervention group
Group type: COMPARATOR
Intervention: Inactive solution (NaCl) presented as an effective treatment
Number of subjects: 48
Study 25408218 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Brain Ageing Cognitive Training (HBA‐CT)
Number of subjects: 64
Study 25408218 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control
Number of subjects: 64
Study 23347341 — intervention group
Group type: EXPERIMENTAL
Intervention: AndroGel 1% 5 g, 7.5 g, or 10 g once daily for 6 months (Study 1)
Number of subjects: 283
Study 23347341 — intervention group
Group type: COMPARATOR
Intervention: AndroGel 1% 7.5 g once daily titrated as needed (Study 2)
Number of subjects: 283
Study 23347341 — intervention group
Group type: COMPARATOR
Intervention: AndroGel 1% 5 g once daily (Study 3)
Number of subjects: 283
Study 23347341 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmarketing data from 2001 to 2011
Number of subjects: 283
Study 21185967 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding (BF)
Number of subjects: 450
Study 21185967 — intervention group
Group type: COMPARATOR
Intervention: Mixed feeding (MF)
Number of subjects: 450
Study 21185967 — intervention group
Group type: COMPARATOR
Intervention: Formula feeding (FF)
Number of subjects: 450
Study 19296208 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal powder formulation
Number of subjects: 0
Study 19296208 — intervention group
Group type: COMPARATOR
Intervention: Commercial nasal liquid spray
Number of subjects: 0
Study 19296208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual tablet
Number of subjects: 0
Study 18031872 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg with AS02B adjuvant candidate vaccine plus lamivudine daily for 52 weeks
Number of subjects: 195
Study 18031872 — intervention group
Group type: COMPARATOR
Intervention: lamivudine daily alone
Number of subjects: 195
Study 14727216 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir (800 mg) and Ritonavir (100 mg) twice a day with Rifampin (300 mg every day for 4 days)
Number of subjects: 6
Study 11383979 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 8
Study 11383979 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 15 mg
Number of subjects: 8
Study 11383979 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 8
Study 11383979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9629648 — intervention group
Group type: EXPERIMENTAL
Intervention: Group sequential method based on the sequential conditional probability ratio test
Number of subjects: 0
Study 9629648 — intervention group
Group type: EXPERIMENTAL
Intervention: Group sequential method
Number of subjects: 0
Study 9629648 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential test
Number of subjects: 0
Study 8067842 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated membrane oxygenators (100 IU/kg heparin)
Number of subjects: 30
Study 8067842 — intervention group
Group type: COMPARATOR
Intervention: Noncoated control membrane oxygenators (300 IU/kg heparin)
Number of subjects: 30
Study 2646416 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant therapy
Number of subjects: 19
Study 2646416 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution)
Number of subjects: 19
Study 31489293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 40 mg/m2 (weekly)
Number of subjects: 60
Study 31489293 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2 (3 weekly)
Number of subjects: 60
Study 25908501 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic massage (effleurage, kneading, and trigger point therapy) for 10 minutes, four times per week for 4 weeks
Number of subjects: 10
Study 25908501 — intervention group
Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 10
Study 26228408 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT group
Number of subjects: 60
Study 26228408 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT group
Number of subjects: 60
Study 23189997 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingualised occlusion
Number of subjects: 30
Study 23189997 — intervention group
Group type: COMPARATOR
Intervention: Bilaterally balanced occlusion
Number of subjects: 30
Study 21275915 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 740
Study 21275915 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc deficiency
Number of subjects: 740
Study 21275915 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B-12 deficiency
Number of subjects: 740
Study 21275915 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate deficiency
Number of subjects: 740
Study 21275915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascaris infestation
Number of subjects: 740
Study 21275915 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal variation
Number of subjects: 740
Study 20011888 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroanalgesia
Number of subjects: 30
Study 20011888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16952489 — intervention group
Group type: EXPERIMENTAL
Intervention: Tariquidar (150 mg over 30 minutes)
Number of subjects: 8
Study 16952489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 15589636 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive management
Number of subjects: 188
Study 15589636 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 188
Study 11418151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cases containing threats from the patient or their relatives (n=630)
Number of subjects: 1260
Study 11418151 — intervention group
Group type: COMPARATOR
Intervention: No threats (control group, n=630)
Number of subjects: 1260
Study 9349914 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment data from clinical studies
Number of subjects: 1323
Study 8406149 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid fibre (250 ml)
Number of subjects: 10
Study 8406149 — intervention group
Group type: COMPARATOR
Intervention: Placebo (250 ml)
Number of subjects: 10
Study 3779341 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet suit
Number of subjects: 16
Study 3779341 — intervention group
Group type: COMPARATOR
Intervention: No wet suit
Number of subjects: 16
Study 31629347 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 days of blueberries (4DAY)
Number of subjects: 14
Study 31629347 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 14
Study 31629347 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 days of placebo followed by 2 days of blueberries (2DAY)
Number of subjects: 14
Study 30021691 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of montelukast/levocetirizine 10/5 mg
Number of subjects: 0
Study 30021691 — intervention group
Group type: COMPARATOR
Intervention: Separate tablets of montelukast and levocetirizine
Number of subjects: 0
Study 30021691 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study 27180088 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 0
Study 27180088 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim methadone
Number of subjects: 0
Study 27180088 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation plus medications
Number of subjects: 0
Study 27180088 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication alone
Number of subjects: 0
Study 27180088 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment-as-usual (ETAU)
Number of subjects: 0
Study 25223180 — intervention group
Group type: EXPERIMENTAL
Intervention: Radix Astragali and Rehmanniae Radix combined with glucocorticoid (GC)
Number of subjects: 52
Study 25223180 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (mainly by GC and cyclophosphamide)
Number of subjects: 52
Study 22102323 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Dissemination Strategy (EDS)
Number of subjects: 68
Study 22102323 — intervention group
Group type: COMPARATOR
Intervention: Basic Dissemination Strategy (BDS)
Number of subjects: 68
Study 22102323 — intervention group
Group type: EXPERIMENTAL
Intervention: GSS use overall
Number of subjects: 68
Study 19284663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (13 group sessions over 1 year, complemented by 3 individual home visits, tailored to literacy needs and cultural preferences, delivered in Spanish)
Number of subjects: 0
Study 19284663 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 17343767 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to increase fatty fish intake
Number of subjects: 5147
Study 17343767 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to eat oily fish or take fish oil
Number of subjects: 5147
Study 17343767 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to eat more fruit and vegetables
Number of subjects: 5147
Study 15525654 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapist-led assessment
Number of subjects: 321
Study 15525654 — intervention group
Group type: COMPARATOR
Intervention: Social worker-led assessment
Number of subjects: 321
Study 11939870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 11939870 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication
Number of subjects: 75
Study 9708081 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopatch dressing (Johnson & Johnson Medical Inc.) used for insertion-site management of CVCs
Number of subjects: 33
Study 9708081 — intervention group
Group type: COMPARATOR
Intervention: Opsite IV 3000 alone (control group)
Number of subjects: 33
Study 8560598 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐ORS (50 g/L)
Number of subjects: 79
Study 8560598 — intervention group
Group type: COMPARATOR
Intervention: G‐ORS
Number of subjects: 79
Study 1537131 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (2.7 g/day of eicosapentaenoic acid, 1.8 g/day of docosahexaenoic acid)
Number of subjects: 205
Study 1537131 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 205
Study 1537131 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of omega-3 fatty acids > 0.15 g/day
Number of subjects: 205
Study 6147905 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 90
Study 6147905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 6147905 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 90
Study 31316037 — intervention group
Group type: EXPERIMENTAL
Intervention: Hangekobokuto (HKT)
Number of subjects: 34
Study 28593748 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable diacetylmorphine
Number of subjects: 0
Study 28593748 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable hydromorphone
Number of subjects: 0
Study 27622998 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic therapy (DT) with midodrine and rifaximin (n=400)
Number of subjects: 600
Study 27622998 — intervention group
Group type: COMPARATOR
Intervention: Diuretic therapy (DT) only (n=200)
Number of subjects: 600
Study 24357105 — intervention group
Group type: EXPERIMENTAL
Intervention: Brussels sprouts (high glucobrassicin concentration)
Number of subjects: 25
Study 24357105 — intervention group
Group type: COMPARATOR
Intervention: Cabbage (low glucobrassicin concentration)
Number of subjects: 25
Study 22632139 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based intervention consisting of four sessions of motivational interviewing (MI) and cognitive behavioural therapy (CBT)
Number of subjects: 160
Study 22632139 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control
Number of subjects: 160
Study 19361872 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (40 mg administered three times daily)
Number of subjects: 87
Study 19361872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 18162561 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 25
Study 18162561 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (Ex)
Number of subjects: 25
Study 15860914 — intervention group
Group type: EXPERIMENTAL
Intervention: Early supported discharge (ESD)
Number of subjects: 320
Study 15860914 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute stroke unit care combined with ESD
Number of subjects: 320
Study 15860914 — intervention group
Group type: COMPARATOR
Intervention: Traditional stroke care
Number of subjects: 320
Study 12527975 — intervention group
Group type: EXPERIMENTAL
Intervention: Even pacing
Number of subjects: 9
Study 12527975 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pacing
Number of subjects: 9
Study 12527975 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pacing
Number of subjects: 9
Study 10659099 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive palliative care
Number of subjects: 0
Study 10659099 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 0
Study 8087261 — intervention group
Group type: EXPERIMENTAL
Intervention: Monostrut (MS)
Number of subjects: 403
Study 8087261 — intervention group
Group type: COMPARATOR
Intervention: Medtronic-Hall (MH)
Number of subjects: 403
Study 2625616 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine HCl 5%-tropicamide 0.8% combination mydriatic (Phenyltrope)
Number of subjects: 0
Study 2625616 — intervention group
Group type: COMPARATOR
Intervention: Tropicamide 1% alone
Number of subjects: 0
Study 857369 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70 (2 X 500 ml i.v.)
Number of subjects: 86
Study 857369 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 86
Study 31327083 — intervention group
Group type: EXPERIMENTAL
Intervention: Local application of doxycycline-loaded PLGA nanospheres (DOXY)
Number of subjects: 40
Study 31327083 — intervention group
Group type: COMPARATOR
Intervention: Local application of placebo PLGA nanospheres (PLAC)
Number of subjects: 40
Study 31188437 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic oligofructose-enriched inulin
Number of subjects: 43
Study 31188437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 28592037 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii 500 mg twice a day for 21 days
Number of subjects: 163
Study 28592037 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 163
Study 26288285 — intervention group
Group type: EXPERIMENTAL
Intervention: APTPA (500 mg glucosamine hydrochloride and 500 mg chondroitin sulfate) + melaxen (3 mg melatonin 30-40 min before sleep)
Number of subjects: 178
Study 26288285 — intervention group
Group type: EXPERIMENTAL
Intervention: APTPA (1 tablet twice a day) + melaxen (3 mg melatonin 30-40 min before sleep)
Number of subjects: 178
Study 26288285 — intervention group
Group type: EXPERIMENTAL
Intervention: APTPA (1 tablet twice a day) + diclofenac (25 mg 2-3 times a day) + melaxen (3 mg melatonin 30-40 min before sleep)
Number of subjects: 178
Study 26288285 — intervention group
Group type: COMPARATOR
Intervention: APTPA (1 tablet twice a day) + diclofenac (25 mg 2-3 times a day)
Number of subjects: 178
Study 26288285 — intervention group
Group type: COMPARATOR
Intervention: APTPA (1 tablet twice a day) + diclofenac (25 mg 2-3 times a day) without melaxen
Number of subjects: 178
Study 23131463 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Complication Scale (PFCS)
Number of subjects: 977
Study 23131463 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Clavien‐Dindo scores
Number of subjects: 977
Study 21396091 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole vaginal pessaries (100 mg) for 6 days
Number of subjects: 3208
Study 21396091 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no treatment, routine antenatal care)
Number of subjects: 3208
Study 18287162 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treatment with 1 g sachets of HR (2 g/d total) plus topical HR 2% gel applied 3 times daily at the internal perimalleolar region
Number of subjects: 0
Study 18287162 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treatment only (same dosage)
Number of subjects: 0
Study 18287162 — intervention group
Group type: EXPERIMENTAL
Intervention: Light elastic compression stockings
Number of subjects: 0
Study 18287162 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals without treatment (control group)
Number of subjects: 0
Study 16844506 — intervention group
Group type: EXPERIMENTAL
Intervention: Mole-mapping diagram
Number of subjects: 88